Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges

Jan 29, 2025Cardiovascular diabetology

GLP-1 drugs and protection against heart and metabolism diseases: past progress and future challenges

AI simplified

GLP-1 TherapiesGLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have expanded their therapeutic applications beyond glycemic control in type 2 diabetes and obesity.

  • GLP-1RAs are associated with cardiovascular, renal, and hepatic benefits.
  • Recent clinical trials highlight the diverse effects of GLP-1RAs on various cardiometabolic conditions.
  • The discovery of GLP-1 has been a key milestone in the evolution of treatments for these diseases.
  • Future challenges include understanding the mechanisms of cardiometabolic protection offered by GLP-1RAs.

AI simplified

Key numbers

3 of 5
3 of 5
GLP-1RAs evaluated in major cardiovascular outcomes trials.
40 weeks
40 weeks
Duration of the SURPASS-2 trial evaluating tirzepatide.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.
View full text (PDF) ↗View full text (HTML) ↗

Related papers

Apr '25
How well newer GLP-1RA drugs work when added to SGLT2i treatment in type 2 diabetes
top 2% journal
cited by 15 papers
comparative study
Jan '20
How SGLT2 Inhibitors and GLP-1 Receptor Agonists May Lower Heart Disease Risk: Completed and Ongoing Mechanism Studies
top 5% journal
cited by 50 papers
journal article
Aug '24
Key health outcomes in type 2 diabetes linked to SGLT2 inhibitors and GLP-1 receptor agonists
cited by 3 papers
journal article
Nov '21
Tirzepatide, a new medicine that activates two blood sugar hormones, as a potential heart and metabolism treatment
top 2% journal
cited by 90 papers
journal article
Dec '20
Glucagon-like peptide-1 receptor agonists' effects on blood sugar control and body measurements in diabetic patients with fatty liver disease
top 20% journal
cited by 16 papers
systematic review
Nov '24
Updated evidence on heart and kidney effects of GLP-1 drugs alone and combined with SGLT2 inhibitors and finerenone
top 2% journal
cited by 27 papers
journal article

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #28
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
6 days ago3 studies
issue #27
GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans
1 week ago7 studies
issue #26
86.5% of patients on semaglutide or tirzepatide lost at least 5% of body weight at 6 months in Medicaid study
2 weeks ago7 studies
issue #25
GLP-1 drugs linked to 20% lower dementia risk in diabetic kidney patients
3 weeks ago7 studies
issue #24
Tirzepatide beats semaglutide for weight loss by 6.1% in head-to-head comparison
4 weeks ago7 studies
issue #23
Bariatric Surgery vs. GLP-1s for cardiovascular risk
5 weeks ago7 studies
issue #22
GLP-1 drugs linked to better pregnancy rates in PCOS women and reduced cancer risk in diabetes patients
6 weeks ago7 studies
issue #21
GLP-1 drugs may fight addiction, and reduce alcohol consumption
7 weeks ago7 studies
issue #20
GLP-1 drugs show promise for kidney transplant patients and Alzheimer's, but may increase eye problems
8 weeks ago7 studies
issue #19
GLP-1 drugs cut heart attack risk by 22% vs competitors, but may increase vision loss risk
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief